Literature DB >> 6601484

Clinical characteristics of patients with rheumatic disorders who possess antibodies against ribonucleoprotein particles.

G G Williamson, J Pennebaker, J A Boyle.   

Abstract

IgG was purified from 91 serum samples obtained from patients with systemic rheumatic diseases and examined for the presence of antinuclear antibodies reactive with small ribonucleoprotein (RNP) complexes. Antibody specificity was determined by autoradiographic detection of 32P labeled RNA which had been separated by polyacrylamide gel electrophoresis. This RNA was extracted from immune complexes formed by adding purified IgG to a homogenate of 32P labeled HeLa cells. Anti-RNP antibodies were detected in 70% of these samples. Specific antibodies detected were anti-(U1)-RNP (35%), anti-Sm (30%), anti-Ro (24%), and anti-La (10%). Other antibodies (9%) were reactive with structures containing 5S and 5.8S RNA or 4S RNA. There was a significant relationship between the presence of anti-RNP antibodies in patients with systemic lupus erythematosus (SLE) (78%) as opposed to their presence in patients with non-SLE rheumatic disorders (45%). However, taken individually, anti-Ro was the only antibody whose presence in SLE patients (30%) was significantly greater than its presence in non-SLE patients (5%). Vasculitis was the only clinical manifestation found to correlate with the presence of a particular antibody, anti(U1)RNP. There is some suggestion of a racial distribution of antibody types.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601484     DOI: 10.1002/art.1780260409

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

2.  Autoimmune sera reactive with Sm antigen contain high levels of RNP-like antibodies.

Authors:  W H Reeves; D E Fisher; R G Lahita; H G Kunkel
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

3.  Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases.

Authors:  B Combe; M Rucheton; H Graafland; V Lussiez; C Brunel; J Sany
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

4.  Purification of the Sm nuclear autoantigen. Detection and clinical significance of IgM antibody.

Authors:  K M Pollard; E M Tan
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

5.  Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens.

Authors:  M Field; D G Williams; P Charles; R N Maini
Journal:  Ann Rheum Dis       Date:  1988-10       Impact factor: 19.103

6.  The dinucleotide repeat polymorphism in the 3'UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus.

Authors:  M J Citores; I Rua-Figueroa; C Rodriguez-Gallego; A Durántez; M I García-Laorden; C Rodríguez-Lozano; J C Rodríguez-Pérez; J A Vargas; P Pérez-Aciego
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

7.  Molecular analysis of the RNA and protein components recognized by anti-La(SS-B) autoantibodies.

Authors:  L J McNeilage; S Whittingham; I Jack; I R MacKay
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

8.  Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting.

Authors:  W J Habets; D J de Rooij; M H Hoet; L B van de Putte; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

Review 9.  A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus.

Authors:  Xin Huang; Qing Zhang; Huilin Zhang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-22       Impact factor: 8.667

Review 10.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.